IL-1 receptor antagonist defect (DIRA) in a pediatric patient, receiving adalimumab with good clinical response.
Juan Carlos Bustamante-OgandoSelma Scheffler-MendozaMarco Antonio Yamazaki-NakashimadaMarimar Saez-de-OcarizPublished in: International journal of dermatology (2021)
Keyphrases